医学博士, 信州大学

胸部悪性腫瘍

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.
Araki T, Kanda S, Horinouchi H, Ohe Y
Jpn J Clin Oncol, 53(7), 547-561, 2023年

Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)
Araki T, Kanda S, Komatsu M, Sonehara K, Tateishi K, Takada M, 3 Akane Kato, Yamamoto M, Nishie K, Hama M, Agatsuma T, Kakizaki Y, Yoshiike F, Matsuo A, Chiaki T, Samizo K, Takagi Y, Yamaura M, Hanaoka M, Koizumi T
Transl Lung Cancer, 12(6), 1320-1327, 2023年

Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients
Araki T, Kanda S, Ide T, Sonehara K, Komatsu M, Tateishi K, Minagawa T, Kiniwa Y, Kawakami S, Nomura S, Okuyama R, Hanaoka M, Koizumi T
ESMO Open, 8(6), 102030, 2023年

Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region
Ide T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Hayashi R, Yasumoto K, Hirono Y, Makino T, Yano S, Koizumi T
BMC Pulmonary Medicine, 23(1), 228, 2023年

EGFR mutation and ALK fusion-positive non-small cell lung cancer: a multicenter prospective cohort study in Nagano Prefecture, Japan
Kobayashi T, Kanda S, Takeishi K, Morozumi N, Yamamoto R, Yoshiike F, Takizawa H, Takada M, Yamamoto M, Nishie K, Takasuna K, Agatsuma T, Hama M, Tanaka H, Matsuo A, Morikawa A, Hanaoka M, Koizumi T
Oncology in Clinical Practice, 19(5), 339-345, 2023年

Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study
Kobayashi T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Tanaka Y, Nakazawa Y, Ito K, Hayashi R, Yasumoto K, Uramoto H, Hirono Y, Makino T, Nakada M, Yano S, Koizumi T
BMC Pulmonary Medicine, 23(1), 322, 2023年

Epidemiological and Therapeutic Analyses in Lung Cancer Patients Over 80 Years Old in the Hokushin Region: A Retrospective Hospital Administrative Database Study
Koizumi T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Tanaka Y, Tomita R, Araki T, Hayashi R, Yasumoto K, Uramoto H, Hirono Y, Makino T, Nakada M, Yano S
Clin Lung Cancer, 4(2), 145-152, 2023年

Clinical analysis of extrapulmonary neuroendocrine carcinoma: a retrospective and single institution experience
Okumura T, Noguchi T, Sekiguchi N, Kobayashi T, Kanda S, Ida K, Minagawa T, Tokumaru S, Umemura T, Koizumi T
Chemotherapy , 68(2), 87-94, 2023年

Successful resection after first-line lenvatinib therapy in an advanced thymic carcinoma
Shimura M, Miura K, Koizumi T, Kanda S, Mishima S, Hara D, Matsuoka S, Eguchi T, Hamanaka K, Uehara T, Shimizu K
Thorac Cancer, 14, 1640-1643, 2023年

Treatment Outcomes in Patients with Atypical EGFR-positive Non-small Cell Lung Cancer in Nagano Prefecture, Japan.
Agatsuma T, Kanda S, Yamamoto R, Ono Y, Nishie K, Tanaka H, Matsuo A, Shibutani M, Koizumi T
信州医学雑誌, 70(6), 397-405, 2022年12月

Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy
Araki T, Tateishi K, Komatsu M, Sonehara K, Wasamoto S, Koyama S, Yoshiike F, Hama M, Nishie K, Kondo D, Agatsuma T, Kato A, Takata M, Kanda S, Hanaoka M, Koizumi T
Thorac Cancer, 13(14), 2031-2040, 2022年

Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy
Araki T, Tateishi K, Komatsu M, Sonehara K, Kanda S, Hanaoka M, Koizumi T
Thorac Cancer, 13(7), 1006-1013, 2022年

Factors Affecting Nivolumab Therapy Outcome in Patients with Head and Neck Cancer: A Single-Center Analysis
Iwasa Y, Yokota Y, Kitoh R, Mori K, Tsukada K, Sekiguchi N, Fukushima T, Kobayashi T, Kanda S, Takumi Y, Koizumi T
ONCOLOGY, 100(4), 203-211, 2022年

Syndrome of Inappropriate Antidiuretic Hormone Secretion as the Initial Presentation in a Patient with Stage I Small-cell Lung Cancer
Koizumi T, Kobayashi T, Kanda S, Fukushima T, Muranaka F, Miura K, Asaka S
Intern Med, 61(5), 709-713, 2022年

Epidemiology of neuroendocrine neoplasmas in Japan: based on analysis of hospital-based cancer registry data, 2009 – 2015
Koizumi T, Otsuki K, Tanaka Y, Kanda S
BMC Endocr Disord, 22(1), 105, 2022年

Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database
Matsuoka S, Koizumi T, Otsuki K, Tanaka Y, Kanda S, Ide S, Mishima S, Takeda T, Miura K, Eguchi T, Hamanaka K, Shimizu K
Cancer Epidemiol, 77, 102116, 2022年

Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant
Hibino H, Sakiyama N, Makino Y, Makihara-Ando R, Horinouchi H, Fujiwara Y, Kanda S, Goto Y, Yoshida T, Okuma Y, Shinno Y, Murakami S, Hashimoto H, Akiyoshi T, Imaoka A, Ohe Y, Yamaguchi M, Ohtani H
Eur J Clin Pharmacol, 78(4), 613-621, 2022年

Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients
Inaba Higashiyama R, Horinouchi H, Kuchiba A, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y
J Cancer Res Clin Oncol, 149(7), 3185-3191, 2022年

Clinical Analysis of Extrapulmonary Neuroendocrine Carcinoma: A Retrospective and Single Institution Experience
Okumura T, Noguchi T, Sekiguchi N, Kobayashi T, Kanda S, Ida K, Minagawa T, Tokumaru S, Umemura T, Koizumi T
Chemotherapy, 68(2), 87-94, 2022年

Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab
Araki T, Tateishi K, Sonehara K, Hirota S, Komatsu M, Yamamoto M, Kanda S, Kuraishi H, Hanaoka M, Koizumi T
Thorac Cancer, 12(5), 603-612, 2021年

A Case of Sinonasal Undifferentiated Carcinoma Sucessfully Responding to Chemoradiotherapy
Matsushita Hirohide, Ozawa Takesumi, Sekiguchi Nodoka, Fukushima Toshirou, Kobayashi Takashi, Kanda Shintaro, Koizumi Tomonobu
Shinshu Medical Journal, 69(3), 121-126, 2021年

化学療法中にGrowing Teratoma Syndromeを呈した縦隔胚細胞性腫瘍の1例
加藤斐菜子、福嶋敏郎、小林孝至、関口和、神田慎太郎、小泉知展
癌と化学療法, 47, 1497-1500, 2020年

Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with EGFR-mutated non-small cell lung cancer: a retrospective study
Yoshida K, Kanda S, Shiraishi H, Goto K, Itahashi K, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y
J Thorac Dis, 11(4), 1347-1354, 2019年

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
Udagawa H, Akamatsu H, Tanaka K, Takeda M, Kanda S, Kirita K, Teraoka S, Nakagawa K, Fujiwara Y, Yasuda I, Okubo S, Shintani M, Kosloski MP, Scripture C, Tamura T, Okamoto I
Lung Cance, 135, 145-150, 2019年

Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer
Tamura N, Horinouchi H, Sekine K, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y
Thorac Cancer, 10(5), 1141-1148, 2019年

Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute
Sonehara K, Tateishi K, Komatsu M, Yamamoto H, Hanaoka M, Kanda S, Koizumi T
Chemotherapy, 64(3)(129-137), 2019年

Mixed response to osimertinib and the beneficial effects of additional local therapy
Shinno Y, Goto Y, Sato J, Morita R, Matsumoto Y, Murakami S, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y
Thorac Cancer, 10(4)(738-743), 2019年

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer
Shibaki R, Murakami S, Shinno Y, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Motoi N, Yamamoto N, Ohe Y
Thorac Cancer, 10(4), 815-822, 2019年

Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease
Shibaki R, Murakami S, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Kusumoto M, Yamamoto N, Ohe Y
Med Oncol, 36(6), 49, 2019年

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer
Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T
Clin Lung Cancer, 20(3), e317-e328, 2019年

A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Ce
Naito T, Udagawa H, Sato J, Horinouchi H, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Zenke Y, Kirita K, Matsumoto S, Yoh K, Niho S, Motoi N, Ohe Y, Ishii G, Goto K
J Thorac Oncol, 14(10), 1818-1827, 2019年

Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis
Masuda K, Fujiwara Y, Shinno Y, Mizuno T, Sato J, Morita R, Matsumoto Y, Murakami S, Goto Y, Kanda S, Horinouchi H, Yamamoto N, Ohe Y
J Thorac Dis, 11(7), 2965-2972, 2019年

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
Makino Y, Makihara-Ando R, Ogawa T, Sato H, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Ohe Y, Yamamoto N
Cancer Sci, 110(11), 3573-3583, 2019年

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption
Kikuchi K, Nozawa K, Yamazaki N, Nakai Y, Higashiyama A, Asano M, Fujiwara Y, Kanda S, Ohe Y, Takashima A, Boku N, Inoue A, Takahashi M, Mori T, Taguchi O, Inoue Y, Mizutani H
J Dermatol, 46(1), 18-25, 2019年

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer
Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T
Clin Lung Cancer, S1525-7304(18), 30355-3, 2018年

Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
Seki Y, Fujiwara Y, Kohno T, Yoshida K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Yamamoto N, Kuwano K, Ohe Y
ESMO Open, 8(3(2)), e000292, 2018年

Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial
Horinouchi H, Kubota K, Miyanaga A, Nakamichi S, Seike M, Gemma A, Yamane Y, Kurimoto F, Sakai H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T, Ohe Y
ESMO Open, 29(3(1)), e000288, 2018年

Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited
Sato J, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Ohe Y
J Thorac Dis, 10(3), 1696-1702, 2018年

Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations
Shinno Y, Goto Y, Watanabe S, Sato J, Morita R, Matsumoto Y, Murakami S, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y
ESMO Open, 28(3), e000399, 2018年

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
Sekine K, Kanda S, Kanda S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Ohe Y
Lung Cancer, 124, 179-188, 2018年

Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions
Ohara S, Kanda S, Okuma H, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Ito Y, Yamamoto N, Usui K, Homma S, Ohe Y
Jpn J Clin Oncol, 48(1), 82-88, 2018年

【免疫療法の進歩と問題点】 免疫チェックポイント阻害薬と化学療法の併用
関根克敏, 神田慎太郎
腫瘍内科, 20(2), 100-105, 2018年

A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.
Kanda S, Niho S, Kurata T, Nomura S, Kawashima Y, Yoneshima Y, Yokoyama T, Watanabe Y, Tanaka H, Fujiwara Y, Zenke Y, Azuma K, Yamaguchi H, Toyozawa R, Hosomi Y, Murakami H, Hara S, Bessho A, Yamamoto N, Ohe Y
アメリカ臨床腫瘍学会, 2023年06月02日

肛門管原発の神経内分泌癌に対して化学放射線療法が奏功した一例
溝口雅弘、小泉知展、小林孝至、神田慎太郎
第119回日本内科学会総会・講演会

3次化学療法まで行って残存腫瘍切除をなし得た兄妹発症の縦隔胚細胞腫瘍の1例
神田慎太郎、小林孝至、小泉知展、江口隆、濱中一敏、清水公裕
第121回日本癌学会中部支部学術集会

International Association for the Study of Lung Cancer

European Society for Medical Oncology

American Society of Clinical Oncology

日本呼吸器内視鏡学会

日本肺癌学会

日本臨床腫瘍学会

日本呼吸器学会

日本内科学会

JCOG1404/WJOG8214L　 EGFR遺伝子変異陽性進行非扁平上皮非小細胞肺癌に対するゲフィチニブ単剤療法とゲフィチニブにシスプラチン＋ペメトレキセドを途中挿入する治療とのランダム化比較試験（AGAIN）